Kinnate Biopharma Inc (KNTE) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kinnate Biopharma Inc   (NASDAQ: KNTE)

Kinnate Biopharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Kinnate Biopharma Inc in the fourth quarter 2023?
Kinnate Biopharma Inc recorded a cumulative net loss of $-113 million during 12 months ending in the fourth quarter 2023, resulting in a negative return on equity (ROE) of -59.91%.

Within the Major Pharmaceutical Preparations industry 243 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2023 from 3540 to 4081.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Equity Change -28.7 % -30.57 % -27.8 % -24.7 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -113 -127 -127 -122 -116
Return On Equity (TTM) -59.91 % -62.31 % -57.01 % -50.53 % -44.66 %
KNTE's Total Ranking # 4081 # 3540 # 3554 # 3548 # 4068
Equity (TTM) in Millions 159 172 198 223 223
Seq. Equity Change -7.59 % -12.75 % -11.29 % -0.32 % -10.02 %
Seq. Net Income Change - - - - -

Back to KNTE Management Effectiveness >> KNTE's 5 Years Annual ROE >> Compare KNTE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 244
Sector # 547
Overall # 4081

Return On Equity Statistics
High Average Low
-25.64 %
-44.81 %
-62.31 %
(Dec 31 2021)   (Sep 30 2023)





KNTE Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021

Total Equity in Millions 159 223 319 0 0
Y / Y Equity Change -28.7 % -30.05 % - - -
Net Income in Millions -113 -116 -90 0 0
Y / Y Net Income Change - - - - -
Return On Equity -70.7 % -52.03 % -28.1 % - -

Back to KNTE Management Effectiveness >> KNTE's 5 Years Annual ROE >> Compare KNTE ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KNTE's' Return on Equity at Yahoo Finance
KNTE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KNTE's Competitors
Subscribers only: Roe for Kinnate Biopharma Inc 's Suppliers
Subscribers only: Return On Equity for KNTE's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE

Date modified: 2026-08-31T01:01:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.